Treatment-Resistant Depression Treatment Market Snapshot (2023 to 2033)
The global treatment-resistant depression treatment market size is expected to be valued at US$ 1.69 Billion in 2023. With the increasing prevalence of depression and anxiety disorders in adults, coupled with the aging population, the overall demand for Treatment-Resistant Therapeutics Treatment is projected to grow at a CAGR of 9.0% between 2023 and 2033, totaling around US$ 4.0 Billion by 2033.
The rising occurrence of Treatment-Resistant Depression has generated consciousness regarding its treatment. Various market players are developing advanced drugs that can be administered through nasal and intravenous routes rather than the traditional oral route of administration. The traditional antidepressants used for this disorder treatment require at least 4 to 6 weeks to produce an effect with a risk of incomplete or poor outcomes through the oral route of administration, whereas the intranasal has been found to produce better results within hours of administration.
For instance, in January 2022, as per the article published by Pharmacopsychiatry, the novel pipeline antidepressant MIJ821 of Novartis Pharmaceuticals demonstrated a more significant reduction in depressive episodes within 24 hours of administration via infusion weekly among patients.
In addition, the overall findings displayed that treatment with intranasal esketamine in amalgamation with a novel oral antidepressant was more efficient than a placebo plus an oral administration. The intranasal esketamine showcased a prompt drop in depressive symptoms and postponed its relapse time. Such increasing research & development for advanced drugs through other routes of administration is projected to surge the demand for drugs, thereby augmenting the overall market growth.
Data Points
Key Statistics
Treatment-Resistant Depression Therapeutics Market Value 2023
US$ 1.69 Billion
Treatment-Resistant Depression Therapeutics Market Projected Value (2033)
US$ 4.0 Billion
Treatment-Resistant Depression Therapeutics Market CAGR (2023 to 2033)
9.0%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Treatment-Resistant Depression Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for treatment-resistant depression therapeutics is projected to increase at a CAGR of 9.0% during the forecast period between 2023 and 2033, reaching a total of US$ 4.0 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.3%.
According to Future Market Insights, a market research and competitive intelligence provider, the Treatment-Resistant Depression Therapeutics market was valued at US$ 1.55 Billion in 2022. As per the World Health Organization (WHO), the prevalence of mental health disorders as well as conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.
According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment. Moreover, several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in the depression treatment market.
Which Drivers underpin Treatment-Resistant Depression Treatment Industry Expansion?
Increasing Drug Development Projectsto Fuel the Market Growth
The rise in the prevalence of Treatment-Resistant Depression and the presence of few treatment options has stimulated the market players to initiate full-fledged research and development activities. Various major market players are focusing on developing new and innovative therapies in the market, citing the clinical benefits and a significant unmet need in treating the disorder globally.
Additionally, it is the leading cause of worldwide disability as conventional therapies are ineffective in a large patient pool, and novel therapies are needed to cater to this growing demand. Also, various pharmaceutical, as well as life science companies, are actively investing in clinical trials of potential pipeline candidates to introduce novel products for treatment. Further, such active participation from the public and private players in developing potential candidates under investigational studies escalates the demand for resistant depression treatment around the globe.
Increasing Prevalence of TRD Globallyto Accelerate the Market Growth
The increase in the prevalence of this mood disorder is one of the major factors that is projected to boost the growth of the TRD Treatment market. TRD occurs when an individual hasn't responded to doses of two different antidepressants taken for an adequate time, usually six weeks. The increase in the prevalence of this medical condition has increased the demand for resistant depression therapeutics.
In addition, according to Springer's research article published in August 2021, major depression disorders affect over 300 million people worldwide, and approximately one-third of patients with MDD have treatment-resistant depression. The prevalence is also associated with disproportionate healthcare costs that have significant direct and indirect cost implications, which places considerable strain on healthcare and social resources.
The variability in the type of healthcare setting as well as accessibility to quality healthcare across the countries to assess unmet needs and treatment failure increases the demand for effective therapeutic measures. Such a rising prevalence of this disorder and disproportionate healthcare costs, which varies across the globe, are anticipated to surge the demand for an effective treatment thereby, fostering the overall treatment growth over the analysis period.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of Treatment-Resistant Depression Treatment Market?
Poor Management of Disorders to Restrain the Market Growth
Despite increasing investment from market players in the TRD project for developing an effective therapeutic measure, there is poor management of this mood disorder, resulting in significant variations in how patients are being managed in real-world practice.
Moreover, the lack of clarity in diagnosing patients is a significant challenge for its treatment. Patients drop out or discontinue treatment due to poor or no positive outcomes. In addition, a cultural and social stigma toward reporting non-responsiveness to treatment, lack of therapeutic options, and inadequate guidelines for managing patients are cumulatively responsible for restraining the market growth.
According to a December 2020 study published by NIH, for the management of TRD, 41.0% of physicians reported treatment discontinuation and loss to follow-up as the top challenge, while 15.0% indicated a lack of therapeutic options as their biggest challenge. Another 14.0% and 13.0% were related to a lack of standardized TRD definitions and specific guidelines, respectively. In addition, the lack of clarity in guidelines for the diagnosis and management of this mood disorder patients, coupled with limited therapeutic measures is expected to hinder the market growth over the analysis period.
Region-wise Insights
Will North America Continue Dominance in the Global Treatment-Resistant Depression Treatment Market?
Advanced Healthcare Infrastructure in the Region to Fuel the Market Growth
The treatment-resistant depression therapeutics market in North America is expected to accumulate the highest market share of 50% in 2023. North America is the most lucrative region along with the highest market share. Factors such as the advanced healthcare infrastructure and healthcare spending are anticipated to fuel the growth of the Treatment-Resistant Depression Market during the forecast period. Also, increasing the adoption rate and demand will propel the treatment-resistance depression treatment market in this region.
In addition, in recent years, there has been a growing rate of adoption, and increasing demand for treatment-resistant depression is also expected to drive the regional market. The region is expected to hold the highest CAGR of 8.8% during the forecast period.
How Will the Growth of the Treatment-Resistant Depression Treatment Market unfold in Asia Pacific?
Growing Awareness Regarding Mental Disorders in the Region to Fuel the Market Growth
The treatment-resistant depression therapeutics market in Asia Pacific is expected to accumulate the highest market share of 49% in 2023. Asia Pacific is the most lucrative region along with the highest market share.
Asia Pacific is opening up the previously held taboo of mental health. With growing awareness about mental disorders, depression, and mental health, the regional segment of Asia Pacific is expected to show a promising rate of growth and give rise to lucrative business opportunities for the development of the market in the coming years. The region is expected to hold the highest CAGR of 8.7% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By Drug Type, which Treatment-Resistant Depression Treatment Category will remain prominent?
NMDA Segment to beat Competition in Untiring Market
On the basis of drug type, the global Treatment-Resistant Depression Therapeutics market is dominated by the NMDA Segment, which accounts for a share of 49%. The growth of the NMDA segment is attributed to the increasing research studies for developing NMDA drugs to improve treatment outcomes.
Moreover, the larger patient population suffering from this disorder and FDA approval of NMDA drugs developed by the key market are expected to fuel segmental growth in the coming years. The segment is expected to hold a CAGR of 8.8% over the analysis period.
By Distribution Channel, which Treatment-Resistant Depression Treatment Category dominates?
Hospital Pharmacies Segment to Drive the Treatment-Resistant Depression Therapeutics Market
Based on the Distribution Channel, the hospital pharmacies segment is expected to witness a significant growth of 47% in 2022, and the trend is expected to continue during the forecast period.
In the treatment of this mood disorder, a prescription for drugs from a medical professional is needed, this is a crucial reason attributable to the segment's growth. In addition, the expansion of hospital pharmacies owing to increasing investment by the public sector in the healthcare infrastructure in emerging countries is predicted to augment the segmental growth during the forecast period. The segment is expected to hold a CAGR of 8.7% over the analysis period.
Who are the Leading Players in the Treatment-Resistant Depression Treatment Market?
Prominent players in the treatment-resistant depression therapeutics market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.
Recent Developments:
In August 2022, Merck Sharp & Dohme LLC initiated Phase II A Clinical Trial to evaluate the safety and efficacy of MK-1942 among treatment-resistant depression patients.
In July 2022, Novartis Pharmaceuticals announced that it would initiate a Phase 2 clinical trial of MIJ821(ketamine) for treatment-resistant depressive disorders in September 2022.
In May 2022, COMPASS Pathways presented positive data for the Phase IIbstudy of COMP360 psilocybin therapy for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans.
In February 2022, Denova Biopharma secured USA FDA approval to initiate a Phase 2b clinical trial to analyze the efficacy and safety of DB104 (liafensine) in patients with a treatment-resistant mood disorder.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 9% from 2023 to 2033
Market Value in 2023
US$ 1.69 Billion
Market Value in 2033
US$ 4 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Type
Distribution Channel
Region
Regions Covered
North America
Europe
Asia Pacific
Latin America
Middle East and Africa (MEA)
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
China
Japan
South Korea
India
Malaysia
Singapore
Thailand
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Eli Lilly and Company
GlaxoSmithKline
Pfizer Inc.
Janssen Pharmaceuticals
AbbVie Inc.
AstraZeneca
H. Lundbeck A/S
Sandoz International GmbH
Par Pharmaceutical Companies Inc.
Otsuka Holdings Co., Ltd.
Customization & Pricing
Available upon Request
Key Segments Covered in the Treatment-Resistant Depression Treatment Industry Analysis
Treatment-Resistant Depression Treatment Market by Drug Type:
NMDA
Antidepressants
Antipsychotics
Others
Treatment-Resistant Depression Therapeutics Market by Distribution Channel:
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
Treatment-Resistant Depression Treatment Market by Region:
North America
Latin America
Europe
South Asia & Pacific
East Asia
Middle East & Africa
Frequently Asked Questions
What was the market value for treatment-resistant depression treatment in 2022?
As of 2022, the market for Treatment-Resistant Depression Treatment was valued at US$ 1.55 Billion, as per FMI
At what value did the treatment-resistant depression treatment market close in 2023?
By 2023-end, demand for treatment-resistant depression treatment closed at a value of US$ 1.69 Billion
What was the last 4 years’ value CAGR for treatment-resistant depression treatment?
From 2018 to 2022, Treatment-Resistant Depression Treatment demand expanded at a CAGR of 3.3%
What is the projected forecast CAGR for the treatment-resistant depression treatment industry from 2023 to 2033?
From 2023 to 2033, treatment-resistant depression treatment demand is expected to flourish at a CAGR of 9%
According to FMI, what is the anticipated market value for treatment-resistant depression treatment in 2033?
By 2033, the market value of treatment-resistant depression treatment is expected to reach US$ 4 Billion
By drug type, which category ranks first with regard to treatment-resistant depression treatment?
By drug type, the NMDA segment of the treatment-resistant depression treatment constitutes the bulk of the market share of 49% in 2022
By distribution channel, which category ranks first with regard to treatment-resistant depression treatment?
By distribution channel, the hospital pharmacies segment dominates the market with a share of 47% in 2022.
Table of Content
1. Executive Summary | Treatment-Resistant Depression Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Billion) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. NMDA
5.3.2. Antidepressants
5.3.3. Antipsychotics
5.3.4. Other Drug Types
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Billion) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Drug Stores & Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia & Pacific
7.3.5. East Asia
7.3.6. Middle East and Africa(MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Australia
11.2.1.6. New Zealand
11.2.1.7. Rest of South Asia & Pacific
11.2.2. By Drug Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa(MEA)
13.2.2. By Drug Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Type
14.1.2.2. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Type
14.2.2.2. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Type
14.3.2.2. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Type
14.4.2.2. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Type
14.5.2.2. By Distribution Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Type
14.6.2.2. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Type
14.7.2.2. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Type
14.8.2.2. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Type
14.9.2.2. By Distribution Channel
14.10. India
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Type
14.10.2.2. By Distribution Channel
14.11. Malaysia
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Type
14.11.2.2. By Distribution Channel
14.12. Singapore
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Type
14.12.2.2. By Distribution Channel
14.13. Thailand
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Type
14.13.2.2. By Distribution Channel
14.14. China
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Type
14.14.2.2. By Distribution Channel
14.15. Japan
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Type
14.15.2.2. By Distribution Channel
14.16. South Korea
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Type
14.16.2.2. By Distribution Channel
14.17. Australia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Type
14.17.2.2. By Distribution Channel
14.18. New Zealand
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Type
14.18.2.2. By Distribution Channel
14.19. GCC Countries
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Type
14.19.2.2. By Distribution Channel
14.20. South Africa
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Type
14.20.2.2. By Distribution Channel
14.21. Israel
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2022
14.21.2.1. By Drug Type
14.21.2.2. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Type
15.3.3. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Eli Lilly Company
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. GlaxoSmithKline
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Pfizer Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Janssen Pharmaceuticals
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. AbbVie Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. AstraZeneca
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. H. Lundbeck
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Sandoz International GmbH
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Par Pharmaceutical Companies Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Otsuka Holdings Co. Ltd.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Billion) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 3: Global Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 6: North America Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 12: Europe Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 13: South Asia & Pacific Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 14: South Asia & Pacific Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 15: South Asia & Pacific Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 16: East Asia Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 18: East Asia Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Table 19: MEA Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 20: MEA Market Value (US$ Billion) Forecast by Drug Type, 2018 to 2033
Table 21: MEA Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 2: Global Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Billion) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Billion) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 10: Global Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug Type, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 17: North America Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 25: North America Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug Type, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 47: Europe Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 48: Europe Market Value (US$ Billion) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 55: Europe Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Market Attractiveness by Drug Type, 2023 to 2033
Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia & Pacific Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 62: South Asia & Pacific Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 63: South Asia & Pacific Market Value (US$ Billion) by Country, 2023 to 2033
Figure 64: South Asia & Pacific Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 65: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia & Pacific Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 68: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 69: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 70: South Asia & Pacific Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 71: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: South Asia & Pacific Market Attractiveness by Drug Type, 2023 to 2033
Figure 74: South Asia & Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: South Asia & Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 77: East Asia Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 78: East Asia Market Value (US$ Billion) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 85: East Asia Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Drug Type, 2023 to 2033
Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: MEA Market Value (US$ Billion) by Drug Type, 2023 to 2033
Figure 92: MEA Market Value (US$ Billion) by Distribution Channel, 2023 to 2033
Figure 93: MEA Market Value (US$ Billion) by Country, 2023 to 2033
Figure 94: MEA Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 95: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: MEA Market Value (US$ Billion) Analysis by Drug Type, 2018 to 2033
Figure 98: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 99: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 100: MEA Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033
Figure 101: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: MEA Market Attractiveness by Drug Type, 2023 to 2033
Figure 104: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: MEA Market Attractiveness by Country, 2023 to 2033
